A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension

DOI: 10.21037/cdt.2019.03.02

Keywords: Pulmonary arterial hypertension (PAH), drug safety, endothelin receptor antagonists (ERAs), bosentan, ambrisentan

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text